Allan Zingeler, BS, brings nearly 30 years of business management, medical device commercialization, and President/CEO-level experience in the medical device Afib industry. Allan has a successful track record of creating value for shareholders and helped lead a prior catheter device company that pioneered the cryo-balloon (CryoCath) in the Afib space from start-up to $40M in annual sales and $400M (10x sales) acquisition by Medtronic.

Steven Mickelsen, MD, is the founder and CMO and brings over 15 years of research experience in heart rhythms and an in-depth understanding of this highly specialized field. Dr. Mickelsen was a Howard Hughes Research Scholar at the National Heart, Lung, and Blood Institute (NHLBI) from 2004-2005, trained in Internal Medicine at Mayo Clinic from 2007-2010, and is now at University of Iowa Hospitals and Clinics as an Electrophysiology Fellow.

Gary Long, BS, PhD, is an electrical engineer and VP R&D who has worked in early product research and development for the past 32 years and spent the last 24 years on medical device development both on the start-up side and for J&J. Gary has 60+ patents, and more importantly, valuable insight into what truly defines minimal invasive procedures as well as effective research and development strategies and tactics in the medical device arena.

Howard C Dittrich, MD, FACC is serving on the Board of Directors and has been involved as Chief Medical Officer (CMO) of multiple life science companies from start-up to acquisitions ranging $350-560 million. This includes NovaCardia, acquired in 2007 by Merck & Co., Corthera, acquired in 2009 by Novartis, and TargeGen, acquired in 2010 by Sanofi Aventis. Dr. Dittrich brings extensive experience and a network of investors & strategic partners.

John Slump, BBA, is serving on the Board of Directors for Iowa Approach and brings medical device start-up experience and CFO-level expertise as well as a finance/accounting educational background. Most recently as Founder/CFO of Corvida Medical, Mr. Slump has led fundraising efforts, securing about $10M in start-up capital - with 1/3 NIH grants and other non-dilutive funds, capitalizing the company to FDA approval & initial commercialization.